

1 **Title:** Recipient/Donor HLA and CMV matching in recipients of T cell depleted
2 unrelated donor haematopoietic cell transplants

3
4
5 **Short title:** Donor factors in transplant outcome

6
7 **Authors:** Bronwen E Shaw^{1,2}, Neema P Mayor^{1,3}, Richard M Szydlo^{1,4}, Will P
8 Bultitude¹, Chloe Anthias^{1,5}, Keiren Kirkland⁶, Julia Perry⁶, Andrew Clark⁷,
9 Stephen Mackinnon⁸, David I Marks⁹, Antonio Pagliuca¹⁰, Michael N Potter⁵, Nigel
10 H Russell¹¹, Kirsty Thomson⁸, J Alejandro Madrigal^{1,3}, Steven G E Marsh^{1,3}

11
12 **Affiliations:**

- 13 ¹ Anthony Nolan Research Institute, Royal Free Hospital, London, UK
14 ² CIBMTR and Froedtert and the Medical College of Wisconsin Clinical Cancer
15 Center, Wisconsin, WI, USA
16 ³ UCL Cancer Institute, Royal Free Campus, London, UK
17 ⁴ Imperial College London, UK
18 ⁵ Royal Marsden NHS Foundation Trust, Sutton, UK
19 ⁶ BSBMT, Guy's Hospital, London, UK
20 ⁷ West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, UK
21 ⁸ University College London Hospitals, London, UK
22 ⁹ University Hospitals Bristol NHS Trust, Bristol, UK
23 ¹⁰ Kings College Hospital, London, UK
24 ¹¹ Centre for Clinical Haematology, Nottingham University Hospital, Nottingham,
25 UK

26
27
28 **Corresponding author:** Bronwen E Shaw, MD, PhD, Froedtert and the Medical
29 College of Wisconsin Clinical Cancer Center, 9200 W. Wisconsin Avenue, Suite
30 C5500, Milwaukee, WI, USA
31 Phone: +1-414-805-0700
32 Email: beshaw@mcw.edu
33 Fax: +1-414-805-0714

34
35
36 **Word count:**

37 Abstract: 199

38 Manuscript: 3173

39
40 References: 37

41 Tables: 4

42 Figures: 2

43
44 None of the authors have any relevant conflict of interest to report and all
45 authors have approved the final version of the manuscript. There was no
46 direct funding source for this study.

49 **Recipient/Donor HLA and CMV matching in recipients of T cell depleted**
50 **unrelated donor haematopoietic cell transplants**

51

52 Bronwen E Shaw, Neema P Mayor, Richard M Szydlo, Will P Bultitude, Chloe
53 Anthias, Keiren Kirkland, Julia Perry, Andrew Clark, Stephen Mackinnon, David I
54 Marks, Antonio Pagliuca, Michael N Potter, Nigel H Russell, Kirsty Thomson, J
55 Alejandro Madrigal, Steven G E Marsh

56

57 **Abstract**

58

59 Improving haematopoietic cell transplantation outcomes by selection of an HLA
60 matched unrelated donor is best practice, however donor selection by secondary
61 characteristics is controversial. We studied 1271 recipients with haematological
62 malignancies who underwent T cell depleted allografts and who had complete
63 data on HLA matching status for six loci (HLA-A, -B, -C, -DRB1, -DQB1, -DPB1) and
64 clinical outcome data. 5-year overall survival was 40.6%. HLA mismatching (at
65 HLA-A, -B, -C, -DRB1, -DQB1) (Relative Risk (RR) 1.22, 95% CI 1.2-1.5, p=0.033 for
66 1 mismatch and RR 1.46, 95% CI 1.1-1.9, p=0.009 for >1 mismatch) and CMV
67 mismatching (RR 1.37, 95% CI 1.2-1.6, p<0.001) were significantly associated
68 with inferior survival. Donors under 30 years were associated with a trend
69 towards better survival (RR 1.17, 95% CI 0.99-1.4, p=0.069). In a multivariate
70 model for mortality combining CMV and HLA match status, we found a RR of 1.36
71 (95% CI 1.1-1.7, p=0.003) for HLA matched/CMV mismatched, a RR of 1.22 (95%
72 CI 0.99-1.5, p=0.062) for HLA mismatched/CMV matched and a RR of 1.81 (95%

73 CI 1.4-2.3, $p < 0.001$) for HLA/ CMV mismatched, compared to the HLA/CMV
74 matched recipients. These data suggest that HLA and CMV matching status should
75 be considered when selecting unrelated donors and that CMV matching may
76 abrogate the effect of an HLA mismatch.

77

78

79 **Introduction**

80

81 Haematopoietic cell transplantation (HCT) is curative for many recipients
82 suffering from haematological and immunological disorders. Survival using
83 unrelated donors (UD) has improved significantly over time and is now equal to
84 that of sibling transplants in many settings.(1) A reason for this improvement is
85 the enormous expansion in the internationally available UD pool, with over 25
86 million donors listed on Bone Marrow Donors Worldwide (BMDW) in 2015
87 (<http://www.bmdw.org/>accessed 20/4/2015). HLA matching for 10/10 loci is
88 often considered the gold standard, but the importance of HLA-DQB1 matching
89 has been questioned.(2, 3) Conversely, the additional benefit to matching for
90 DPB1 has been increasingly studied.(4-6) In addition, studies report a differential
91 impact of single allele mismatches on transplant outcomes.(2, 7, 8) Due to the
92 expansion in volunteer donors numbers recipients now often have a choice
93 between several equally HLA matched donors and in this setting secondary donor
94 characteristics such as donor age, gender, parity, CMV serostatus and ABO type
95 should be taken into account.(3, 9) Although these factors may currently be
96 considered by the team making the final donor selection, no widespread

97 internationally agreed selection algorithms are available. Selection of these
98 factors has changed significantly over time. CMV seronegative donors (D-) were
99 originally chosen for all recipients. More recently a CMV seropositive donor has
100 been preferred for a CMV positive recipient, however this remains controversial,
101 despite some studies supporting it.(10, 11) Studies show that younger donors
102 generally result in improved outcomes, but the impact of ABO mismatches and
103 the use of female donors have produced conflicting results. (3, 9)

104

105 The aim of this study was to analyse the impact of HLA and non-HLA donor
106 factors on transplant outcomes and to identify those factors important in donor
107 selection.

108

109 **Recipients, material and methods**

110

111 **Study population**

112

113 The final study population includes 1271 UK recipients, both children and adults,
114 transplanted for a haematological malignancy, from September 1996 to October
115 2011, from an UD through Anthony Nolan. 1370 paired samples that were
116 collected pre-transplant or pre-donation for recipients and donor respectively
117 and stored in the sample repository were successfully typed, however 99
118 recipients were not included in the final study population due to incomplete
119 clinical data. Both recipient and donor were required to have two field
120 (previously 4-digit) allele typing results at six HLA loci (HLA-A, -B, -C, -DRB1, -
121 DQB1, -DPB1). Clinical data were collected by the Anthony Nolan Research

122 Institute in collaboration with the British Society for Blood and Marrow
123 Transplantation, using standard post transplant reporting forms. Standard
124 definitions for primary graft failure (PGF), graft versus host disease (GVHD) and
125 non-relapse mortality (NRM) were used. Relapse was defined as clinical evidence
126 of disease. The EBMT score was calculated based on the publication by Gratwohl
127 *et al.*(12) CMV prophylaxis was not routinely given, instead screening and pre-
128 emptive treatment strategies were used.

129 **Ethical permission**

130 The study has ethical approval from the United Kingdom's National Research
131 Ethics Service (www.myresearchproject.org.uk, application number MREC
132 01/8/31). All recipients and donors signed informed consent.

133 **Statistical Methods**

134 Probability curves were calculated using the Kaplan-Meier method for survival
135 and the cumulative incidence procedure for NRM and relapse. Time intervals
136 were calculated relative to the date of transplantation, until the event of interest
137 (or competing event), or until the date of last follow-up. Groups were compared
138 using either the log rank test or Gray's test as appropriate. Factors found to be
139 significant at the $P < 0.1$ level were entered into either Cox regression or Fine and
140 Gray (13) models, using a backward stepping procedure to find the best model.
141 Incomplete time to event data for PGF and Grade II-IV aGVHD resulted in these
142 outcomes being described as simple proportions, with logistic regression analysis
143 being utilised to find significant factors associated with each outcome. All
144 analyses were performed using either SPSS version 22 software (SPSS, Inc.,

145 Chicago, IL) or R (14). All statistical tests were 2 sided, and $P < 0.05$ was used to
146 indicate statistical significance.

147 **Results**

148

149 Recipient and donor factors are shown in Table 1 arranged by transplantation
150 era. Disease for which transplantation was performed were acute leukaemia (581,
151 46%), myelodysplasia (221, 17%), chronic leukaemia (174, 14%), lymphoma
152 (198, 16%), myeloma (46, 4%) and other (51, 4%). 94% of the population
153 received T cell depletion (TCD) with Alemtuzumab. As expected, the use of
154 myeloablative conditioning decreased over the eras with a corresponding
155 increase in the use of Peripheral Blood Stem Cells (PBSC). Recipients were
156 significantly older in the later eras. There was a reduction in the number of HLA
157 mismatched donors over time. Donors were also more likely to be younger and
158 CMV seropositive donors (D+) were more likely to be selected for CMV
159 seropositive recipients (R+) in the later eras.

160

161 The 5yr probability of survival for the whole group was 40.6%, with NRM at 1, 3
162 and 5 years of 26.5%, 34.3% and 37.4% respectively. The relapse risk at 1, 3 and
163 5 years was 29.2 %, 39.2% and 42.1% respectively. Overall PGF rate was 3.8%.
164 Acute GVHD was present in 28% of recipients (grade 2 in 18%, grade 3/4 in 10%).

165

166 **Factors implicated in recipient survival and mortality**

167

168 Results of the univariate analysis of recipient and donor factors are shown in
169 Table 2. Older recipients ($p=0.005$), R+ ($p=0.013$), those who had a previous
170 autograft ($p=0.001$) and intermediate or poor EBMT risk status ($p<0.001$) had a
171 worse OS. There was a trend to a worse OS with the use of Bone Marrow (BM)
172 compared to PBSC ($p=0.078$).

173

174 Recipients matched for 10/10 HLA alleles had significantly better OS and reduced
175 NRM compared to those matched at 9/10 or $<9/10$ (5yr OS: 43.1 vs 35.6 vs 28.4
176 respectively, $p=0.001$ (Figure 1) and NRM at 1yr : 20.3% vs 26.0% vs 33.4%
177 respectively, $p=0.007$). Considering individual locus mismatches compared to
178 10/10 matched recipients, mismatching for HLA-B ($p=0.011$) and -DQB1
179 ($p=0.03$) resulted in a significantly worse survival, while mismatching for HLA-A
180 ($p=0.17$), -C ($p=0.28$) or -DRB1 ($p=0.75$) resulted in no statistically significant
181 difference in survival (table 2).

182

183 HLA-DPB1 matching was not associated with a statistically significant survival
184 advantage (5yr OS for 12/12 was 46.5% vs 42.5% in 10/10 matches, $p=0.1$). Non-
185 permissive HLA-DPB1 T-cell Epitope (TCE) matching status was associated with a
186 trend towards worse survival and a significantly higher NRM 5yr OS in DPB1 TCE
187 matched, allele matched or TCE mismatched pairs was 43.0%, 41.5%, and 36.9%
188 respectively, $p=0.054$) and NRM at 1 year was 19.3%, 23.6% and 26.4%
189 respectively, $p=0.028$ (Table 2).

190

191 There was no impact of donor CMV on either OS or NRM as an independent
192 variable, however a significant effect was observed for CMV matching status

193 between recipient and donor. Recipients who had a CMV matched donor had an
194 OS of 44.1% vs 32.2% for those who were mismatched ($p<0.001$). Survival in the
195 R+/D+ setting was 40.5% compared to 30.0% in the R+/D-. We also noted a
196 difference in the CMV negative recipient where R-/D- had a survival of 45.3%
197 compared to 37.9% in the R-/D+ (Table 2). NRM at 1 year was 19.1% vs 30.4%
198 for the CMV matched vs mismatched recipients ($p<0.001$) (Table 2). Use of donors
199 under the age of 30 resulted in a better survival (45.3% vs 38.6%, $p=0.01$) and a
200 trend to lower NRM (19.2% vs 27.9%, $p=0.075$). An ABO match or minor
201 mismatch was preferential to a major or bidirectional mismatch (OS: $p=0.011$ and
202 NRM: $p=0.040$).

203

204 In multivariate analysis (Table 3), the only recipient factor resulting in worse OS
205 was older age. Recipients with a previous autograft and/or intermediate or poor
206 EBMT disease risk score had a worse OS. OS and NRM were significantly worse in
207 those who had a transplant prior to 2004 and 2000 respectively. HLA matching
208 remained significant, as those who had >1 HLA mismatch with their donor had a
209 Relative Risk (RR) of 1.43 (95% CI 1.1-1.9, $p=0.016$) for mortality and 1.59 (95%
210 1.1-2.4, $p=0.028$) for NRM. Although there remained a survival detriment when
211 comparing a single mismatch to recipients with a 10/10 matched donor (OS: RR
212 1.21 (95% CI 1.1-1.5), $p=0.042$) there was no significant impact on NRM: RR 1.24
213 (95% CI 0.9-1.6), $p=0.14$). Recipients who were CMV mismatched with their
214 donor had a significant survival detriment (OS: RR 1.40, 95% CI 1.2-1.6, $p<0.001$;
215 NRM: RR 1.63, 95% CI 1.3-2.1, $p<0.001$). Use of donors >30 showed a trend
216 towards worse OS (RR 1.17 (95% CI 0.98-1.4, $p=0.078$), but no impact on NRM. In
217 contrast, recipient/donor gender matching did not impact on OS, while a female

218 donor into a male recipient showed a trend to higher NRM compared to all other
219 gender combinations (RR 1.38, 95% CI, 0.99-1.9, p=0.063). Recipient donor ABO
220 matching status and the DPB1 TCE were not significant for either OS or TRM.

221

222 **Disease Relapse**

223 Four factors were shown to be associated with an increase in disease relapse in
224 univariate analysis, including recipients of a prior autograft (5 yrs: 54.2% vs
225 40.0%, p<0.001); earlier transplant era (p=0.012); BM vs PBSC (45.2% vs 38.7%,
226 p=0.024 and the use a DPB1 TCE or allele matched donor vs a TCE mismatch
227 donor (p=0.036). CMV status of either the patient or donor, or the combinations,
228 were not associated with relapse risk. In multivariate analysis, donor CMV status
229 was the only donor factor associated with relapse (D+: RR 1.23 95% CI 1.1-1.5,
230 p=0.035), whilst prior autograft and era retained significance (Table 4).

231

232 **CMV status in the context of HLA matching**

233

234 We further examined the relationship between recipient/donor CMV and HLA
235 matching (Figure 2a). Outcomes differed significantly based on the four possible
236 combinations (p=<0.001). In the HLA matched setting, survival was significantly
237 better in those who were CMV matched (n=676) compared to CMV mismatched
238 (n=223) (5yr OS 45.9% vs 35.9%, p=0.007). Likewise, in the HLA mismatched
239 setting, CMV matched recipients (n=207) again had a better survival than those
240 who were CMV mismatched (n=122) (5yr OS 38.6% vs 25.8%, p=0.002). These
241 findings were consistent when adjusted for other significant variables in a
242 multivariate analysis (Figure 2b). When compared to the HLA matched, CMV

243 matched recipients: there was a RR 1.36 (95% CI 1.1-1.7, p=0.003) for HLA
244 matched and CMV mismatched, a RR 1.22 (95% CI 0.99-1.5, p=0.062) for HLA
245 mismatched and CMV matched, and a RR 1.81 (95% CI 1.4-2.3, p<0.001) for HLA
246 and CMV mismatched.

247

248 **Impact of donor factors on other outcomes**

249

250 In multivariate analysis, a mismatch of more than one HLA allele (RR 2.9, 95% CI
251 1.2-7.3, p=0.02) and the use of BM (RR 2.9, 95% CI 1.2 – 7.3, p=0.02) resulted in
252 significantly higher PGF. HLA matching (OR 0.63 95%CI 0.5-0.8, p=0.002), the use
253 of BM (OR 0.59, 95% CI 0.4-0.8, p=0.001) and CMV seronegative donors (OR 0.65,
254 95% CI 0.5-0.9, p=0.006) were associated with a lower risk of grade 2-4 aGVHD
255 (Table 4).

256

257 **Discussion**

258

259 Our results show that donor factors remain a critical determinant of outcome in
260 UD HCT, despite the changing trends in transplant practice over recent eras. We
261 found both HLA matching and the recipient/donor match status for pre-
262 transplant CMV serostatus to be the most significant factors determining survival
263 and report the novel finding that avoiding a CMV mismatch may offset the
264 negative impact of an HLA mismatch. In addition, we confirmed the previous
265 observations that HLA matching and donor age impact survival.

266

267 Although the relationship between CMV and HLA matching in this study is a novel
268 finding, it is consistent with observations and proposed mechanisms made in
269 several recent studies. Historically it is well recognised that recipient CMV
270 seropositivity (R+) is associated with an inferior transplant outcome (15, 16), but
271 studies regarding the impact of donor status have produced controversial results
272 (3, 9, 17) and recommendations for donor selection based on this criteria have
273 changed over time. In recent years there is developing consensus around the
274 selection of a CMV seromatched donor for a HCT recipient.

275

276 Individual study results are not consistent with regards to subgroups in which
277 this selection may be relevant. Two recent large EBMT studies report results
278 similar to ours. In 2003, Ljungman *et al* (10) reported that a transplant from a D+
279 was associated with improved OS, event-free survival and decreased TRM
280 compared to a D- in UD SCT. They did not find any difference in GVHD in the
281 seronegative vs seropositive groups. In that study the positive effect of D+ was
282 abrogated by TCD using ATG, but recipients receiving Alemtuzumab (as in our
283 study) were not included. More recently the same group(11) showed an improved
284 survival in R+ transplanted with a D+, however only in the recipients receiving
285 myeloablative conditioning regimens. Although CMV reactivations (and GVHD)
286 were not directly addressed, they found that deaths due to viral causes were less
287 likely in R+/D+, leading them to suggest that the presence of CMV-specific T cells
288 was mediating a protective effect of D+ on survival. Interestingly there was no
289 impact of TCD noted in this study. Neither study addressed the HLA match status.

290

291 As shown in our results, the negative effect of an HLA mismatch may be abrogated
292 somewhat by matching for CMV. The combined immunological effects as well as
293 potential poor graft function due to treatment of CMV and an HLA mismatch
294 (GVHD, immunosuppression and immune deficiency) are likely to be critical and
295 may explain some of the discrepancies in earlier studies. This is supported by the
296 fact that donor CMV serostatus does not appear to have major significance in
297 HLA-identical sibling transplantation outcomes (10, 11) as well as the finding that
298 CMV reactivations are higher in the setting of an HLA mismatch.(18) While the
299 overall rates of clinically significant GVHD were low, HLA mismatching was
300 associated with a significant increase in GVHD as expected.

301

302 Some (10, 18, 19), but not all (20, 21) studies have shown that CMV reactivation
303 and disease are more common in the setting of a CMV mismatch (i.e. R+/D-
304 compared to R+/D+). In the late 1980s it was reported that cells from D+ could
305 result in better outcomes in the TCD setting through reduction in CMV
306 disease.(22) CMV specific T cells transferred with the donor graft could protect
307 against progressive or recurrent CMV reactivation (19, 21) and therefore be
308 associated with better outcomes. This effect could be abrogated or lost by
309 extensive TCD (*ex-vivo* or ATG) or the need for ongoing and intensive
310 immunosuppression such as in GVHD.

311

312 Although, *in-vivo* TCD with Alemtuzumab was used in over 90% of the recipients
313 in our study, it is well recognised that this does not eradicate all T cells and that a
314 degree of CMV-specific immunity is retained in this setting. CMV specific T cells
315 may also be of recipient origin. Peggs *et al.*(23) have recently shown that in the

316 majority of R+/D- recipients receiving TCD (mostly sibling) reduced intensity
317 conditioning (RIC) HCT, recipient-derived T cells provide protection from
318 recurrent CMV infection in the absence of GVHD. However, they stress the
319 importance of avoiding GVHD in this setting to prevent CMV-associated toxicities.
320 In our registry based study, we unfortunately do not have data on CMV
321 reactivations, immune reconstitution (IR) or the chimeric status of recipients post
322 transplant. However, in line with the findings of Peggs *et al's*, the negative effect of
323 donor serostatus (R+/D-) in our study is seen predominantly in those recipients
324 with a co-existing HLA mismatch and consequently an increase in clinical
325 GVHD(data not shown).

326

327 Another possible mechanism for improved outcome may be through a direct (24-
328 26) or indirect (through earlier IR) (27) effect of CMV on reduction of disease
329 relapse post transplant, although this remains controversial.(28-30) Early and
330 robust IR in general has been shown to be associated with improved transplant
331 outcomes.(31) Not surprisingly, CMV specific IR has an important association
332 with a reduction in CMV reactivation and infections.(20, 32) However donor CMV
333 status has also been shown to influence the strength of IR (33) and Zhou *et al.*
334 showed that CMV specific T-cell populations from R+/D+ contained higher levels
335 of functional subsets than R+/D-recipients.(19) We found that the use of CMV
336 seronegative donors was associated with a lower relapse risk.

337

338 HLA matching is important for survival, however in contrast to our previous
339 studies, (5, 34) we did not find a similar survival between a 10/10 and 9/10
340 matched transplant, but rather findings similar to the Lee *et al.* paper (2) showing

341 an incremental survival disadvantage with additional HLA mismatches. Possible
342 reasons for this include a reduction in Alemtuzumab doses in the recent era(35,
343 36) as well as the larger numbers now included in our study giving us greater
344 power to detect a difference. We did see an impact of DQB1 matching on both OS
345 and NRM. This differed from the Lee et al (2) study, however is consistent with
346 the report from the German group(9, 37) which found a higher mortality
347 associated with DQB1 mismatching, in particular if these mismatches were at an
348 antigenic level. As in many studies the type of mismatch may thus be of
349 significance and may differ in the European versus American population. Based
350 on these differences we would recommend matching status continue to be
351 considered for DQB1 as the impact of mismatches remains somewhat
352 controversial. Matching should also be prioritised for HLA-B. A caution is that the
353 number of mismatches in this study was small. Although survival was improved
354 when either allele level or epitope matching for DPB1 was performed as has been
355 previously shown,(4, 6) this was not a significant factor in multivariate analysis.
356 Previously the impact has been seen most commonly in transplant pairs matched
357 for the other HLA alleles, with less of an impact of DPB1 mismatching in $\leq 9/10$
358 matched transplants and we did not perform subset analysis.

359

360 Donor age was significantly associated with transplant outcomes, although the
361 effect in multivariate analysis was borderline. These findings are consistent with
362 several other studies(9, 37) and suggest this factor should be taken into account
363 in donor selection. Although donor gender and ABO matching status both had
364 some impact on transplant outcomes in univariate analysis, these effects were not
365 seen in multivariate analysis. Several other studies have shown conflicting results

366 related to these factors and it is possible that the impact may differ based on the
367 characteristics of the population studied. In addition, small statistical effects may
368 be more difficult to appreciate in smaller datasets.

369

370 In conclusion, our results add to the recent consensus that survival is improved
371 by selecting a CMV matched donor for an UD HCT recipient. We significantly
372 extend these findings by including the influence of HLA matching on this variable
373 and suggest that these factors are closely interrelated.

374

375 Based on these results, and those from recent studies, several donor selection
376 strategies could be proposed. A 10/10 HLA matched donor remains best and
377 selection of a CMV matched donor is preferable. This is particularly relevant in the
378 setting of a R+ in the HLA mismatch setting. If no D+ is available in this setting an
379 alternative stem cell source, such as umbilical cord blood which has been shown
380 to be associated with less GVHD, should be considered. Where a R+/D-
381 combination cannot be avoided, active strategies to avoid GVHD should be
382 undertaken. Finally our results suggest that donor characteristics should not be
383 considered in isolation, but as a 'package' and individualised based on recipient
384 characteristics.

385

386 **Authorship**

387 BES, NM, SM, JAM designed the study, collected and curated the samples and data,
388 performed the analysis and wrote the paper. BES, NM, WB performed the
389 laboratory typing. RS performed the statistical analysis. KK and JS collected and
390 contributed the clinical data. BES, CA, AC, SM, DM, AP, MP, NR, KT contributed

391 patient data and samples. All of the authors contributed to the writing and review
392 of the manuscript. None of the authors have any relevant conflict of interest to
393 declare.

394

395 **Acknowledgements**

396

397 We would like to thank all of the transplant centre data managers and co-
398 ordinators who provided clinical data or research samples for this study.

399

400 **Conflict of interest**

401 None of the authors have any relevant conflict of interest to report

402

403 **References**

- 404 1. Ottinger H, Ferencik S, Beelen D, Lindemann M, Peceny R, Elmaagacli A, et
405 al. Hematopoietic stem cell transplantation: contrasting the outcome of
406 transplantations from HLA-identical siblings, partially HLA-mismatched related
407 donors, and HLA-matched unrelated donors. *Blood*. 2003;102(3):1131-7.
- 408 2. Lee S, Klein J, Haagenson M, Baxter-Lowe L, Confer D, Eapen M, et al. High-
409 resolution donor-recipient HLA matching contributes to the success of unrelated
410 donor marrow transplantation. *Blood*. 2007;110(13):4576-83.
- 411 3. Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, et al.
412 Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative
413 unrelated allogeneic hematopoietic cell transplantation. *Blood*.
414 2014;124(16):2596-606.
- 415 4. Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon J-D, et al.
416 Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor
417 haemopoietic-cell transplantation: a retrospective study. *The lancet oncology*.
418 2012;13(4):366-74.
- 419 5. Shaw BE, Mayor NP, Russell NH, Apperley JF, Clark RE, Cornish J, et al.
420 Diverging effects of HLA-DPB1 matching status on outcome following unrelated
421 donor transplantation depending on disease stage and the degree of matching for
422 other HLA alleles. *Leukemia : official journal of the Leukemia Society of America,*
423 *Leukemia Research Fund, UK*. 2010;24(1):58-65.
- 424 6. Burt C, Parker A, McQuaker G, Copland M, Brierley C, Little AM, et al. In a
425 12-allele analysis HLA-DPB1 matching is associated with improved OS in

426 leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted
427 PBSCT from unrelated donors. *Bone Marrow Transplant.* 2014;49(5):657-63.

428 7. Morishima Y, Kashiwase K, Matsuo K, Azuma F, Morishima S, Onizuka M, et
429 al. Biological significance of HLA locus matching in unrelated donor bone marrow
430 transplantation. *Blood.* 2015;125(7):1189-97.

431 8. Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M,
432 et al. HLA-C antigen mismatch is associated with worse outcome in unrelated
433 donor peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant.*
434 2011;17(6):885-92.

435 9. Kollman C, Howe C, Anasetti C, Antin J, Davies S, Filipovich A, et al. Donor
436 characteristics as risk factors in recipients after transplantation of bone marrow
437 from unrelated donors: the effect of donor age. *Blood.* 2001;98(7):2043-51.

438 10. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C.
439 Donor CMV serologic status and outcome of CMV-seropositive recipients after
440 unrelated donor stem cell transplantation: an EBMT megafile analysis. *Blood.*
441 2003;102(13):4255-60.

442 11. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al.
443 Donor cytomegalovirus status influences the outcome of allogeneic stem cell
444 transplant: a study by the European group for blood and marrow transplantation.
445 *Clinical infectious diseases : an official publication of the Infectious Diseases*
446 *Society of America.* 2014;59(4):473-81.

447 12. Gratwohl A. The EBMT risk score. *Bone Marrow Transplant.*
448 2012;47(6):749-56.

449 13. Fine J, Gray R. A Proportional Hazards Model for the Subdistribution of a
450 Competing Risk. *Journal of the American Statistical Association.*
451 1999;94(446):496-509.

452 14. R Core Team. R: A language and environment for statistical computing. R
453 Foundation for Statistical Computing, Vienna, Austria 2014 [Available from:
454 <http://www.R-project.org/>].

455 15. Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, et al.
456 Cytomegalovirus seropositivity adversely influences outcome after T-depleted
457 unrelated donor transplant in patients with chronic myeloid leukaemia: the case
458 for tailored graft-versus-host disease prophylaxis. *Br J Haematol.*
459 2001;112(1):228-36.

460 16. Spencer A, Brookes PA, Kaminski E, Hows JM, Szydlo RM, van Rhee F, et al.
461 Cytotoxic T lymphocyte precursor frequency analyses in bone marrow
462 transplantation with volunteer unrelated donors. Value in donor selection.
463 *Transplantation.* 1995;59(9):1302-8.

464 17. Bacigalupo A, Tedone E, Sanna MA, Moro F, Van Lint MT, Grazi G, et al. CMV
465 infections following allogeneic BMT: risk factors, early treatment and correlation
466 with transplant related mortality. *Haematologica.* 1992;77(6):507-13.

467 18. Jaskula E, Bochenska J, Kocwin E, Tarnowska A, Lange A. CMV Serostatus of
468 Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT
469 Patients. *Bone Marrow Res.* 2012;2012:375075.

470 19. Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, et al.
471 Impact of donor CMV status on viral infection and reconstitution of multifunction
472 CMV-specific T cells in CMV-positive transplant recipients. *Blood.*
473 2009;113(25):6465-76.

- 474 20. Moins-Teisserenc H, Busson M, Scieux C, Bajzik V, Cayuela JM, Clave E, et al.
475 Patterns of cytomegalovirus reactivation are associated with distinct evolutive
476 profiles of immune reconstitution after allogeneic hematopoietic stem cell
477 transplantation. *J Infect Dis*. 2008;198(6):818-26.
- 478 21. Pietersma FL, van Dorp S, Minnema MC, Kuball J, Meijer E, Schuurman R, et
479 al. Influence of donor cytomegalovirus (CMV) status on severity of viral
480 reactivation after allogeneic stem cell transplantation in CMV-seropositive
481 recipients. *Clinical infectious diseases : an official publication of the Infectious
482 Diseases Society of America*. 2011;52(7):e144-8.
- 483 22. Grob JP, Grundy JE, Prentice HG, Griffiths PD, Hoffbrand AV, Hughes MD, et
484 al. Immune donors can protect marrow-transplant recipients from severe
485 cytomegalovirus infections. *Lancet*. 1987;1(8536):774-6.
- 486 23. Sellar RS, Vargas FA, Henry JY, Verfuert S, Charrot S, Beaton B, et al. CMV
487 promotes recipient T-cell immunity following reduced-intensity T-cell-depleted
488 HSCT, significantly modulating chimerism status. *Blood*. 2015;125(4):731-9.
- 489 24. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trensche R,
490 Ditschkowski M, et al. Early human cytomegalovirus replication after
491 transplantation is associated with a decreased relapse risk: evidence for a
492 putative virus-versus-leukemia effect in acute myeloid leukemia patients. *Blood*.
493 2011;118(5):1402-12.
- 494 25. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM,
495 et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early
496 protection in acute myeloid leukemia. *Blood*. 2013;122(7):1316-24.
- 497 26. Ito S, Pophali P, Co W, Koklanaris EK, Superata J, Fahle GA, et al. CMV
498 reactivation is associated with a lower incidence of relapse after allo-SCT for CML.
499 *Bone Marrow Transplant*. 2013;48(10):1313-6.
- 500 27. Admiraal R, Chiesa R, Bierings M, Versluijs A, Hiwarkar P, Silva J, et al.
501 Early CD4+ Immune Reconstitution Predicts Probability of Relapse in Pediatric
502 AML after Unrelated Cord Blood Transplantation: Importance of Preventing in
503 Vivo T-Cell Depletion Using Thymoglobulin. *BMT Tandem "Scientific"
504 Meeting2015*.
- 505 28. Thomson KJ, Mackinnon S, Peggs KS. CMV-specific cellular therapy for
506 acute myeloid leukemia? *Blood*. 2012;119(4):1088-90; author reply 90-1.
- 507 29. Busca A, Passera R, Pini M, Zallio F, Dellacasa C, Audisio E, et al. The use of
508 ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients
509 with acute myeloid leukemia receiving grafts from unrelated donors. *Am J
510 Hematol*. 2015;90(6):E117-21.
- 511 30. Mariotti J, Maura F, Spina F, Roncari L, Doderio A, Farina L, et al. Impact of
512 cytomegalovirus replication and cytomegalovirus serostatus on the outcome of
513 patients with B cell lymphoma after allogeneic stem cell transplantation. *Biol
514 Blood Marrow Transplant*. 2014;20(6):885-90.
- 515 31. Moscardo F, Sanz J, Carbonell F, Sanz MA, Larrea L, Montesinos P, et al.
516 Effect of CD8(+) cell content on umbilical cord blood transplantation in adults
517 with hematological malignancies. *Biol Blood Marrow Transplant*.
518 2014;20(11):1744-50.
- 519 32. Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J, et al.
520 Patients at high risk for CMV infection and disease show delayed CD8+ T-cell
521 immune recovery after allogeneic stem cell transplantation. *Bone Marrow
522 Transplant*. 2007;39(5):293-9.

- 523 33. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P. Evaluation of
524 intervention strategy based on CMV-specific immune responses after allogeneic
525 SCT. *Bone Marrow Transplant*. 2007;40(9):865-9.
- 526 34. Shaw B, Gooley T, Malkki M, Madrigal J, Begovich A, Horowitz M, et al. The
527 importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation.
528 *Blood*. 2007;110(13):4560-6.
- 529 35. Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, et al.
530 Impact of in vivo alemtuzumab dose before reduced intensity conditioning and
531 HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and
532 immune reconstitution. *Blood*. 2010;116(16):3080-8.
- 533 36. Jardine L, Publicover A, Bigley V, Hale G, Pearce K, Dickinson A, et al. A
534 comparative study of reduced dose alemtuzumab in matched unrelated donor and
535 related donor reduced intensity transplants. *Br J Haematol*. 2015;168(6):874-81.
- 536 37. Kollman C, Klein JP, Spellman SR, Hassebroek A, Confer DL, Fernandez-
537 Vina M, et al. The Effect of Donor Characteristics On Graft Vs. Host Disease (GVHD)
538 and Survival After Unrelated Donor Transplantation for Hematologic Malignancy.
539 BMT Tandem "Scientific" Meeting; Sunday, February 17, 2013: 10:30 AM-12:00
540 PM2013.
- 541
- 542

543 Figure legends

544

545 Figure 1: Probability of survival curves for groups based on the degree of HLA matching

546 for 10/10 alleles: 10/10 vs 9/10 vs <9/10

547

548 Figure 2: Survival curves for groups based on recipient/donor CMV serostatus and HLA

549 matching status. A. Univariate analysis, B. For an average patient from a Cox regression

550 analysis that included recipient age, disease risk, donor age, era and previous autograft.

551

552

Table 1: Recipient and Donor characteristics, presented by transplantation era

Variable	1996-1999 (N=154)	2000-2003 (N=433)	2004-2007 (N=387)	2008-2011 (N=297)	P-value (<i>comparison of eras</i>)	Overall (N=1271)
HLA Match status						
10/10	98 (64%)	286 (66%)	305 (79%)	244 (82%)	<0.001	933 (73%)
9/10	41 (27%)	100 (23%)	63 (16%)	50 (17%)		254 (20%)
<9/10	15 (10%)	47 (11%)	19 (5%)	3 (1%)		84 (7%)
HLA Match						
10/10	98 (70.5%)	286 (74.1%)	305 (82.9%)	244 (83.0%)	0.007	933 (78.6%)
9/10 A Mismatch	11 (7.9%)	18 (4.7%)	19 (5.2%)	12 (4.1%)		60 (5.1%)
9/10 B Mismatch	2 (1.4%)	11 (2.8%)	5 (1.4%)	4 (1.4%)		22 (1.9%)
9/10 C Mismatch	22 (15.8%)	48 (12.4%)	23 (6.3%)	18 (6.1%)		111 (9.4%)
9/10 DQ Mismatch	6 (4.3%)	20 (5.2%)	15 (4.1%)	12 (4.1%)		53 (4.5%)
9/10 DR Mismatch	0 (0%)	3 (0.8%)	1 (0.3%)	4 (1.4%)		8 (0.7%)
Donor age (years)						
median (range)	34.6 (21-53)	35.5 (19-56)	34.9 (20-60)	33.2 (19-58)	0.073	34.9 (19-60)
missing	1	2	9	2		14
Donor age (years)						
<30	42 (27.5%)	106 (24.6%)	130 (34.4%)	110 (37.3%)	0.001	388 (30.9%)
>30	111 (72.5%)	325 (75.4%)	248 (65.6%)	185 (62.7%)		869 (69.1%)
Duration of disease pre-sct months, median (range)	16.8 (1-245)	15.0 (2-309)	15.3 (2-381)	13.8 (2-187)	0.74	15.0 (1-381)
missing	1	2	9	1		13
Recipient age (years)						
median (range)	29.1 (2-57)	37.3 (2-66)	43.4 (1-72)	51.2 (1-71)	<0.001	40.6 (1-72)
Recipient age (years)						
<20	51 (33.1%)	108 (24.9%)	64 (16.5%)	25 (8.4%)	<0.001	248 (19.5%)
20-39	68 (44.2%)	143 (33.0%)	102 (26.4%)	57 (19.2%)		370 (29.1%)
40-59	35 (22.7%)	168 (38.8%)	182 (47.0%)	139 (46.8%)		524 (41.2%)
≥60	0 (0%)	14 (3.2%)	39 (10.1%)	76 (25.6%)		129 (10.1%)
Recipient gender						
Male	92 (59.7%)	275 (63.5%)	249 (64.3%)	184 (62.0%)	0.76	800 (62.9%)
Female	62 (40.3%)	158 (36.5%)	138 (35.7%)	113 (38.0%)		471 (37.1%)
Disease Risk – EBMT score						
Good	73 (49.3%)	184 (43.6%)	183 (48.5%)	140 (48.4%)	0.19	580 (46.9%)
Intermediate	60 (40.5%)	163 (38.6%)	138 (36.6%)	96 (33.2%)		457 (37.0%)
Poor	15 (10.1%)	75 (17.8%)	56 (14.9%)	53 (18.3%)		199 (16.1%)
Missing	6	11	10	8		35
Recipient / Donor CMV status						
R-/D-	82 (55.0%)	246 (57.1%)	174 (49.3%)	145 (49.2%)	<0.001	647 (52.7%)
R-/D+	22 (14.8%)	36 (8.4%)	23 (6.5%)	20 (6.8%)		101 (8.2%)
R+/D-	27 (18.0%)	88 (20.4%)	73 (20.7%)	56 (19.0%)		244 (19.9%)
R+/D+	18 (12.1%)	61 (14.2%)	83 (23.5%)	74 (25.1%)		236 (19.2%)
Missing	5	2	34	2		43
Recipient / Donor CMV status						
matched	100 (67.1%)	307 (71.2%)	257 (72.8%)	219 (74.2%)	0.44	883 (71.9%)
mismatched	49 (22.9%)	124 (28.8%)	96 (27.2%)	76 (25.8%)		345 (28.1%)
Missing	5	2	34	2		43
Stem cell source						
BM	146 (96.7%)	268 (62.3%)	122 (31.7%)	44 (14.9%)	<0.001	580 (46.0%)
PBSC	5 (3.3%)	162 (37.7%)	263 (68.3%)	252 (85.1%)		682 (54.0%)
Missing	3	3	2	1		9
Conditioning regimen						
Myeloablative	133 (93.7%)	268 (63.8%)	169 (43.7%)	91 (30.6%)	<0.001	661 (53.0%)
Reduced Intensity	9 (6.3%)	152 (36.2%)	218 (56.3%)	206 (69.4%)		585 (47.0%)
Missing	12	13	0	0		25
Previous autograft						
0	138 (89.6%)	367 (84.8%)	315 (81.4%)	259 (87.2%)	0.055	1079 (84.9%)
>0	16 (10.4%)	66 (15.2%)	72 (18.6%)	38 (12.8%)		192 (15.1%)
T-cell depletion (Campath)						
Yes	129 (94.2%)	357 (94.9%)	308 (90.6%)	246 (94.3%)	0.10	1040 (93.4%)
No	8 (5.8%)	19 (5.1)	32 (9.4%)	15 (5.7%)		74 (6.6%)
Missing	17	57	47	36		157

BM-bone marrow; PBSC-peripheral blood stem cells

556
557
558

Table 2: Univariate analyses of Recipient and Donor Factors on OS and NRM and relapse

	N	Survival at 5yrs (%) (95%CI)	p-value	N	NRM at 1yr(%) (95% CI)	p-value	N	Relapse at 5yrs (%) (95%CI)	p-value
Overall	1271	40.6 (38-44)	-	1236	26.5 (24-29)	-	1236	42.1 (39-45)	
HLA match status									
10/10	933	43.1 (40-47)	0.001	905	20.3 (27-23)	0.007	905	42.1 (39-46)	0.96
1 Mismatch	254	35.6 (30-42)		247	26.1 (21-32)		247	41.5 (36-48)	
>1 Mismatch	84	28.4 (20-40)		84	33.4 (24-45)		84	44.1 (34-57)	
HLA Match									
12/12	140	46.5 (38-57)	0.011	134	18.3 (13-26)	0.16	134	44.7 (36-55)	0.97
10/10	793	42.5 (39-46)		771	20.6 (18-24)		771	41.6 (38-46)	
9/10 A Mismatch	60	36.1 (26-51)		57	24.8 (16-39)		57	41.8 (30-58)	
9/10 B Mismatch	22	22.7 (11-49)		21	38.1 (22-67)		21	38.1 (21-68)	
9/10 C Mismatch	111	39.0 (31-49)		110	21.8 (15-31)		110	44.7 (36-55)	
9/10 DR Mismatch	8	46.9 (21-99)		8	12.5 (2-89)		8	25.0 (7-92)	
9/10 DQ Mismatch	53	31.7 (21-48)		51	34.9 (24-52)		51	37.8 (26-55)	
TCE-Matching status									
Match	175	41.5(34-50)	0.054	169	23.6 (18-31)	0.028	169	43.1 (36-52)	0.036
TCEM	639	43.0 (39-47)		623	19.3 (16-23)		623	45.3 (41-50)	
TCED	447	36.9 (32-42)		434	26.4 (23-31)		434	36.8 (32-42)	
HLA A									
10/10	933	43.1 (40-47)	0.17*	905	20.3 (18-23)	0.14	905	42.1 (39-46)	0.99
9/10 A match	194	35.5 (29-43)		190	26.6 (21-34)		190	41.5 (35-49)	
9/10 A Mismatch	60	36.1 (25-51)		57	24.8 (16-39)		57	41.8 (30-58)	
HLA B									
10/10	933	43.1 (40-47)	0.011*	905	20.3 (18-23)	0.059	905	42.1 (39-46)	0.95
9/10 B match	232	36.8 (31-44)		226	25.0 (20-31)		226	41.9 (36-49)	
9/10 B Mismatch	22	22.7 (11-49)		21	38.1 (22-67)		21	38.1 (21-68)	
HLA C									
10/10	933	43.1 (40-47)	0.28*	905	20.3 (18-23)	0.062	905	42.1 (39-46)	0.74
9/10 C match	143	33.1 (26-42)		137	29.7 (23-39)		137	38.8 (31-48)	
9/10 C Mismatch	111	39.0 (31-49)		110	25.8 (19-34)		110	44.7 (36-55)	
HLA DR									
10/10	933	43.1 (40-47)	0.75*	905	20.3 (18-23)	0.11	905	42.1 (39-46)	0.69
9/10 DR match	246	35.3 (30-42)		239	26.6 (22-33)		239	42.1 (36-49)	
9/10 DR Mismatch	8	46.9 (18-78)		8	12.5 (2-89)		8	25.0 (7-92)	
HLA DQ									
10/10	933	43.1 (40-47)	0.03*	905	20.3 (18-23)	0.051	905	42.1 (39-46)	0.95
9/10 DQ match	201	36.7 (30-44)		196	24.0 (19-31)		196	42.4 (36-50)	
9/10 DQ Mismatch	53	31.7 (21-48)		51	34.9 (24-52)		51	37.8 (26-55)	
Donor age (years)									
<30	388	45.3 (40-51)	0.01	376	19.2 (16-27)	0.075	376	39.5 (35-45)	0.18
≥30	869	38.6 (35-42)		846	27.9 (24-32)		846	43.6 (40-47)	
Recipient age (years)									
<20	248	45.7 (39-52)	0.005	248	21.1 (17-27)	0.41	248	40.2 (34-47)	0.07
20-39	370	44.9 (40-50)		370	20.9 (17-26)		370	44.0 (39-50)	
40-59	524	38.5 (34-43)		524	22.5 (19-27)		524	43.6 (39-48)	
≥60	129	23.5 (16-33)		129	29.2 (22-39)		129	34.5 (26-45)	
Recipient CMV									
Negative	749	44.3 (41-48)	0.013	731	20.4 (18-24)	0.057	731	42.6 (39-47)	0.66
Positive	480	35.1 (31-40)		463	25.2 (22-30)		463	42.2 (38-47)	
Donor CMV									
Negative	926	40.9 (38-44)	0.78	899	23.3 (21-26)	0.19	899	40.4 (37-44)	0.076
Positive	344	39.7 (35-46)		336	19.9 (16-25)		336	46.7 (41-53)	
Recipient / Donor CMV									
R-/D-	647	45.3 (41-49)	<0.001	631	19.6 (17-23)	<0.001	631	41.5 (38-46)	0.30
R-/D+	101	37.9 (29-48)		99	25.4 (18-36)		99	49.1 (40-61)	
R+/D-	244	30.0 (24-36)		233	32.6 (27-39)		233	38.9 (33-46)	
R+/D+	236	40.5 (34-48)		230	17.7 (13-24)		230	45.3 (39-53)	
Recipient / Donor CMV									
Matched	883	44.1 (41-48)	<0.001	861	19.1 (17-22)	<0.001	861	42.5 (39-46)	0.61
Mismatched	345	32.2 (28-38)		332	30.4 (26-36)		332	41.9 (37-48)	
Donor Sex									
Male	1022	41.1 (38-45)	0.26	989	20.9 (19-24)	0.011	989	42.0 (39-45)	0.91
Female	249	38.3 (32-45)		247	28.2 (23-35)		247	42.3 (36-49)	
Recipient / Donor Sex									
Other combination	1138	41.3 (38-44)	0.11	1103	21.4 (19-24)	0.018	1103	42.1 (39-45)	0.94
Male / Female	133	34.8 (27-44)		133	30.4 (23-39)		133	42.2 (24-52)	

Stem cell source									
BM	580	38.9 (35-43)	0.078	561	25.0 (22-29)	0.027	561	45.2 (41-50)	0.024
PBSC	682	42.2 (38-47)		666	20.4 (18-24)		666	38.7 (35-43)	
R/D ABO matching									
Match	557	40.9 (37-46)		537	20.0 (17-23)		537	42.0 (38-47)	
Minor mismatch	310	46.5 (41-53)	0.011	303	20.5 (16-26)	0.040	303	39.8 (34-46)	0.69
Major mismatch	283	33.9 (29-40)		277	29.1 (24-35)		277	42.1 (36-49)	
Bidirectional	78	36.8 (27-50)		76	22.8 (15-35)		76	46.4 (36-60)	
Duration of disease pre SCT									
<1y	532	41.7 (37-46)	0.92	579	21.6 (18-26)	0.60	579	41.3 (37-46)	0.83
>1y	736	39.9 (36-44)		704	22.7 (20-26)		704	43.1 (39-47)	
Previous autograft									
0	1079	42.9 (38-44)	0.001	1050	22.3 (20-25)	0.78	1050	40.0 (37-43)	<0.001
>0	192	27.1 (21-35)		186	22.9 (18-30)		186	54.2 (47-62)	
ERA									
96-99	154	40.8 (34-49)		148	33.8 (27-42)		148	44.2 (37-53)	
00-03	433	39.5 (35-44)	0.64	420	20.7 (17-25)	0.003	420	47.2 (43-52)	0.012
04-07	387	42.5 (38-48)		377	20.5 (17-25)		377	39.0 (34-44)	
08-11	297	37.8 (31-46)		291	21.8 (17-27)		291	35.7 (30-43)	
Disease Risk - EBMT score									
Good	580	47.5 (43-52)		563	20.2 (20-27)		563	41.6 (38-46)	
Intermediate	457	34.7 (30-40)	<0.001	444	24.5 (21-29)	0.26	444	42.6 (38-48)	0.17
Poor	199	31.7 (25-40)		194	23.6 (18-31)		194	46.0 (39-54)	
Conditioning regimen									
Myeloablative	661	41.4 (38-45)	0.33	647	24.8 (22-28)	0.016	647	41.2 (38-45)	0.71
Reduced intensity	585	40.0 (36-45)		565	19.8 (17-23)		565	42.4 (38-47)	

BM-bone marrow; PBSC-peripheral blood stem cells; TCE-T cell epitope; TCEM -T cell epitope match; TCED -T cell epitope disparate;

*p-values are between mismatched genotype and 10/10 match

559
560
561
562
563

564 Table 3: Multivariate analysis of Survival and NRM
 565

	Overall Survival			Non Related Mortality		
	N	RR (95% CI)	p-value	N	RR (95% CI)	p-value
HLA Match						
10/10 Match	878	1.00		871	1.00	
1 Mismatch	239	1.21 (1.1-1.5)	0.042	239	1.24 (0.9-1.6)	0.14
>1 Mismatch	77	1.43 (1.1-1.9)	0.016	83	1.59 (1.1-2.4)	0.028
Recipient Donor CMV						
Match	863	1.00		861	1.00	
Mismatch	331	1.40 (1.2-1.6)	<0.001	332	1.63 (1.3-2.1)	<0.001
Recipient age (years)						
<20	221	1.00				
20-39	351	1.07 (0.8-1.4)	0.57			
40-59	497	1.26 (1.0-1.6)	0.047			
>60	125	1.71 (1.3-2.3)	0.001			
Previous autos						
0	1014	1.00				
>0	180	1.42 (1.2-1.8)	0.001			
Donor Age						
<30y	372	1.00				
>30y	822	1.17 (0.98-1.4)	0.078			
ERA						
96-99	142	1.00		143	1.00	
00-03	421	0.84 (0.7-1.1)	0.18	418	0.57 (0.4-0.8)	0.002
04-07	345	0.76 (0.6-1.0)	0.049	343	0.54 (0.4-0.9)	0.002
08-11	286	0.77 (0.6-1.1)	0.078	289	0.60 (0.3-0.7)	0.001
Disease Risk - EBMT						
Good	557	1.00				
Intermediate	444	1.37 (1.2-1.6)	<0.001			
Poor	193	1.33 (1.1-1.7)	0.013			
Recipient / Donor Sex						
Other combination				1061	1.00	
Male / Female				132	1.38 (0.99-1.9)	0.063

566
 567
 568

569
570


Table 4: Multivariate analysis of PGF, aGVHD and Relapse

	Primary Graft Failure			Acute GVHD grade 2-4			Relapse		
	N	OR (95% CI)	p-value	N	OR (95% CI)	p-value	N	RR (95% CI)	p-value
HLA Match									
10/10 Match	872	1.00		882	1.00				
1 Mismatch	233	1.7 (0.8-3.5)	0.15	237	1.52 (1.1 -2.2)	0.01			
>1 Mismatch	76	2.9 (1.2 - 7.3)	0.02	77	1.82 (1.1 - 3.0)	0.022			
Donor CMV									
Negative				875	1.00		899	1.00	
Positive				321	0.65 (0.5-0.9)	0.005	336	1.23 (1.1-1.5)	0.035
Stem cell source									
PBSC	655	1.00		542	1.00				
BM	526	4.23 (1.8-9.7)	0.001	654	0.58 (0.4 -0.8)	0.001			
ERA				134					
96-99				413	1.00		147	1.00	
00-03				372	0.31 (0.2-0.5)	<0.001	420	1.09 (0.8-1.5)	0.54
04-07				277	0.39 (0.2-0.6)	<0.001	377	0.83 (0.6-1.1)	0.21
08-11					0.28 (0.2-0.5)	<0.001	291	0.70 (0.5-0.9)	0.031
Conditioning type									
Reduced	554	1.00							
Intensity									
Myeloablative	627	8.2 (2.5-27.2)	0.001						
Previous autos									
0							1049	1.00	
>0							186	1.55 (1.2-1.9)	<0.001

571

573
574
575
576
577

Figure 1




578
579
580
581

582 Figure 2a

583

584




585

586

587

588
589
590
591

Figure 2b



592
593
594
595
596